|
1
|
Mattiuzzi C and Lippi G: Current cancer
epidemiology. J Epidemiol Glob Health. 9:217–222. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tzanakakis G, Giatagana EM, Kuskov A,
Berdiaki A, Tsatsakis A, Neagu M and Nikitovic D: Proteoglycans in
the pathogenesis of hormone-dependent cancers: Mediators and
effectors. Cancers (Basel). 12:24012020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maciejowski J and de Lange T: Telomeres in
cancer: Tumor suppression and genome instability. Nat Rev Mol Cell
Biol. 18:175–186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shay JW and Wright WE: Telomeres and
telomerase: Three decades of progress. Nat Rev Genet. 20:299–309.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lim CJ and Cech TR: Shaping human
telomeres: From shelterin and CST complexes to telomeric chromatin
organization. Nat Rev Mol Cell Biol. 22:283–298. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dratwa M, Wysoczańska B, Łacina P, Kubik T
and Bogunia-Kubik K: TERT-Regulation and roles in cancer formation.
Front Immunol. 11:29302020. View Article : Google Scholar
|
|
7
|
Hrdličková R, Nehyba J and Bose HR:
Alternatively spliced telomerase reverse transcriptase variants
lacking telomerase activity stimulate cell proliferation. Mol Cell
Biol. 32:4283–4296. 2012. View Article : Google Scholar
|
|
8
|
Sæbøe-Larssen S, Fossberg E and Gaudernack
G: Characterization of novel alternative splicing sites in human
telomerase reverse transcriptase (hTERT): Analysis of expression
and mutual correlation in mRNA isoforms from normal and tumour
tissues. BMC Mol Biol. 7:262006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Listerman I, Sun J, Gazzaniga F, Lukas JL
and Blackburn EH: The major reverse transcriptase-incompetent
splice variant of the human telomerase protein inhibits telomerase
activity but protects from apoptosis. Cancer Res. 73:2817–2828.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takakura M, Kyo S, Kanaya T, Hirano H,
Takeda J, Yutsudo M and Inoue M: Cloning of human telomerase
catalytic subunit (hTERT) gene promoter and identification of
proximal core promoter sequences essential for transcriptional
activation in immortalized and cancer cells. Cancer Res.
59:551–557. 1999.PubMed/NCBI
|
|
11
|
Tsoukalas D, Fragkiadaki P, Docea AO,
Alegakis AK, Sarandi E, Vakonaki E, Salataj E, Kouvidi E, Nikitovic
D, Kovatsi L, et al: Association of nutraceutical supplements with
longer telomere length. Int J Mol Med. 44:218–226. 2019.PubMed/NCBI
|
|
12
|
Vasilopoulos E, Fragkiadaki P, Kalliora C,
Fragou D, Docea AO, Vakonaki E, Tsoukalas D, Calina D, Buga AM,
Georgiadis G, et al: The association of female and male infertility
with telomere length (Review). Int J Mol Med. 44:375–389.
2019.PubMed/NCBI
|
|
13
|
Vakonaki E, Tsiminikaki K, Plaitis S,
Fragkiadaki P, Tsoukalas D, Katsikantami I, Vaki G, Tzatzarakis MN,
Spandidos DA and Tsatsakis AM: Common mental disorders and
association with telomere length. Biomed Rep. 8:111–116.
2018.PubMed/NCBI
|
|
14
|
Razgonova MP, Zakharenko AM, Golokhvast
KS, Thanasoula M, Sarandi E, Nikolouzakis K, Fragkiadaki P,
Tsoukalas D, Spandidos DA and Tsatsakis A: Telomerase and telomeres
in aging theory and chronographic aging theory (Review). Mol Med
Rep. 22:1679–1694. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sfeir A and de Lange T: Removal of
shelterin reveals the telomere end-protection problem. Science.
336:593–597. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blasco MA: Telomeres and human disease:
Ageing, cancer and beyond. Nat Rev Genet. 6:611–622. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jäger K and Walter M: Therapeutic
targeting of telomerase. Genes (Basel). 7:392016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsatsakis A, Tsoukalas D, Fragkiadaki P,
Vakonaki E, Tzatzarakis M, Sarandi E, Nikitovic D, Tsilimidos G and
Alegakis AK: Developing BIOTEL: A Semi-Automated spreadsheet for
estimating telomere length and biological age. Front Genet.
10:842019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dunham MA, Neumann AA, Fasching CL and
Reddel RR: Telomere maintenance by recombination in human cells.
Nat Genet. 26:447–450. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Teng SC and Zakian VA: Telomere-telomere
recombination is an efficient bypass pathway for telomere
maintenance in Saccharomyces cerevisiae. Mol Cell Biol.
19:8083–8093. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cesare A and Reddel R: Alternative
lengthening of telomeres: Models mechanisms and implications. Nat
Rev Genet. 11:319–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Henson J, Neumann AA, Yeager TR and Reddel
RR: Alternative lengthening of telomeres in mammalian cells.
Oncogene. 21:598–610. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heaphy CM, Subhawong AP, Hong SM, Goggins
MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL,
Westra WH, et al: Prevalence of the alternative lengthening of
telomeres telomere maintenance mechanism in human cancer subtypes.
Am J Pathol. 179:1608–1615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Demanelis K, Jasmine F, Chen LS, Chernoff
M, Tong L, Delgado D, Zhang C, Shinkle J, Sabarinathan M, Lin H, et
al: Determinants of telomere length across human tissues. Science.
369:eaaz68762020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Peleteiro B, Padrão P, Castro C, Ferro A,
Morais S and Lunet N: Worldwide burden of gastric cancer in 2012
that could have been prevented by increasing fruit and vegetable
intake and predictions for 2025. Br J Nutr. 115:851–859. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Doherty JA, Grieshober L, Houck JR,
Barnett MJ, Tapsoba JD, Thornquist M, Wang CY, Goodman GE and Chen
C: Telomere length and lung cancer mortality among heavy smokers.
Cancer Epidemiol Biomarkers Prev. 27:829–837. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leão R, Apolónio JD, Lee D, Figueiredo A,
Tabori U and Castelo-Branco P: Mechanisms of human telomerase
reverse transcriptase (hTERT) regulation: Clinical impacts in
cancer. J Biomed Sci. 251:222018. View Article : Google Scholar
|
|
28
|
Barthel FP, Wei W, Tang M,
Martinez-Ledesma E, Hu X, Amin SB, Akdemir KC, Seth S, Song X, Wang
Q, et al: Systematic analysis of telomere length and somatic
alterations in 31 cancer types. Nat Genet. 49:349–357. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Albertson DG: Gene amplification in
cancer. Trends Genet. 22:447–455. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McClintock B: The fusion of broken ends of
chromosomes following nuclear fusion. Proc Natl Acad Sci.
28:458–463. 1942. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Valentijn L, Koster J, Zwijnenburg D,
Hasselt NE, van Sluis P, Volckmann R, van Noesel MM, George RE,
Tytgat GA, Molenaar JJ and Versteeg R: NH-N and 2015 undefined:
TERT rearrangements are frequent in neuroblastoma and identify
aggressive tumors. Nat Genet. 47:1411–1414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kyo S, Takakura M, Fujiwara T and Inoue M:
Understanding and exploiting hTERT promoter regulation for
diagnosis and treatment of human cancers. Wiley Online Libr.
99:1528–1538. 2008.
|
|
33
|
Lewis KA and Tollefsbol TO: Regulation of
the telomerase reverse transcriptase subunit through epigenetic
mechanisms. Front Genet. 7:832016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng L, Montironi R and Lopez-Beltran A:
TERT promoter mutations occur frequently in urothelial papilloma
and papillary urothelial neoplasm of low malignant potential. Eur
Urol. 71:497–498. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Deaton AM and Bird A: CpG islands and the
regulation of transcription. Genes Dev. 25:1010–1022. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Castelo-Branco P, Choufani S, Mack S,
Gallagher D, Zhang C, Lipman T, Zhukova N, Walker EJ, Martin D,
Merino D, et al: Methylation of the TERT promoter and risk
stratification of childhood brain tumours: An integrative genomic
and molecular study. Lancet Oncol. 14:534–542. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Castelo-Branco P, Leão R, Lipman T,
Campbell B, Lee D, Price A, Zhang C, Heidari A, Stephens D, Boerno
S, et al: A cancer specific hypermethylation signature of the TERT
promoter predicts biochemical relapse in prostate cancer: A
retrospective cohort study. Oncotarget. 7:57726–57736. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sepehri Z, Beacon TH, Osman FDS, Jahan S
and Davie JR: DNA methylation and chromatin modifications.
Nutritional Epigenomics. 13–36. 2019. View Article : Google Scholar
|
|
39
|
Bert SA, Robinson MD, Strbenac D, Statham
AL, Song JZ, Hulf T, Sutherland RL, Coolen MW, Stirzaker C and
Clark SJ: Regional Activation of the cancer genome by long-range
epigenetic remodeling. Cancer Cell. 23:9–22. 2013. View Article : Google Scholar
|
|
40
|
Hrdličková R, Nehyba J, Bargmann W and
Bose HR: Multiple tumor suppressor microRNAs regulate telomerase
and TCF7 an important transcriptional regulator of the Wnt pathway.
PLoS One. 9:e869902014. View Article : Google Scholar
|
|
41
|
Mitomo S, Maesawa C, Ogasawara S, Iwaya T,
Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu
N, et al: Downregulation of miR-138 is associated with
overexpression of human telomerase reverse transcriptase protein in
human anaplastic thyroid carcinoma cell lines. Cancer Sci.
99:280–286. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kachuri L, Helby J, Bojesen SE, Christiani
DC, Su L, Wu X, Tardón A, Fernández-Tardón G, Field JK, Davies MP,
et al: Investigation of leukocyte telomere length and genetic
variants in chromosome 5p15.33 as prognostic markers in lung
cancer. Cancer Epidemiol Biomarkers Prev. 28:1228–1237. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xue Y, Guo X, Huang X, Zhu Z, Chen M, Chu
J, Yang G, Wang Q and Kong X: Shortened telomere length in
peripheral blood leukocytes of patients with lung cancer, chronic
obstructive pulmonary disease in a high indoor air pollution region
in China. Mutat Res. 858-860:5032502020. View Article : Google Scholar
|
|
44
|
Steiner B, Ferrucci LM, Mirabello L, Lan
Q, Hu W, Liao LM, Savage SA, De Vivo I, Hayes RB, Rajaraman P, et
al: Association between coffee drinking and telomere length in the
Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
PLoS One. 15:e02269722020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sun B, Wang Y, Kota K, Shi Y, Motlak S,
Makambi K, Loffredo CA, Shields PG, Yang Q, Harris CC and Zheng YL:
Telomere length variation: A potential new telomere biomarker for
lung cancer risk. Lung Cancer. 88:297–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jang JS, Choi YY, Lee WK, Choi JE, Cha SI,
Kim YJ, Kim CH, Kam S, Jung TH and Park JY: Telomere length and the
risk of lung cancer. Cancer Sci. 99:385–1389. 2008. View Article : Google Scholar
|
|
47
|
Sanchez-Espiridion B, Chen M, Chang JY, Lu
C, Chang DW, Roth JA, Wu X and Gu J: Telomere length in peripheral
blood leukocytes and lung cancer risk: A large case-control study
in Caucasians. Cancer Res. 74:2476–2486. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jeon HS, Choi JE, Jung DK, Choi YY, Kang
HG, Lee WK, Yoo SS, Lim JO and Park JY: Telomerase activity and the
risk of lung cancer. J Korean Med Sci. 27:141–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dobija-Kubica K, Zalewska-Ziob M,
Bruliński K, Rogoziński P, Wiczkowski A, Gawrychowska A and
Gawrychowski J: Telomerase activity in non-small cell lung cancer.
Kardiochir Torakochirurgia Pol. 13:15–20. 2016.PubMed/NCBI
|
|
50
|
Li J, Zhang L, Zhu H, Pan W, Zhang N, Li Y
and Yang M: Leukocyte telomere length and clinical outcomes of
advanced lung adenocarcinoma patients with epidermal growth factor
receptor tyrosine kinase inhibitors treatment. DNA Cell Biol.
37:903–908. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang X, Zhao Q, Zhu W, Liu T, Xie SH,
Zhong LX, Cai YY, Li XN, Liang M, Chen W, et al: The association of
telomere length in peripheral blood cells with cancer risk: A
systematic review and meta-analysis of prospective studies. Cancer
Epidemiol Biomarkers Prev. 26:1381–1390. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cao X, Huang M, Zhu M, Fang R, Ma Z, Jiang
T, Dai J, Ma H, Jin G, Shen H, et al: Mendelian randomization study
of telomere length and lung cancer risk in East Asian population.
Cancer Med. 8:7469–7476. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Machiela MJ, Hsiung CA, Shu XO, Seow WJ,
Wang Z, Matsuo K, Hong YC, Seow A, Wu C, Hosgood HD, et al: Genetic
variants associated with longer telomere length are associated with
increased lung cancer risk among never-smoking women in Asia: A
report from the female lung cancer consortium in Asia. Int J
Cancer. 137:311–319. 2015. View Article : Google Scholar
|
|
54
|
Yuan JM, Beckman KB, Wang R, Bull C,
Adams-Haduch J, Huang JY, Jin A, Opresko P, Newman AB, Zheng YL, et
al: Leukocyte telomere length in relation to risk of lung
adenocarcinoma incidence: Findings from the Singapore Chinese
Health Study. Int J Cancer. 142:2234–2243. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
de-Torres JP, Sanchez-Salcedo P,
Bastarrika G, Alcaide AB, Pío R, Pajares MJ, Campo A, Berto J,
Montuenga L, Del Mar Ocon M, et al: Telomere length, COPD and
emphysema as risk factors for lung cancer. Eur Respir J.
49:16015212017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Telomeres Mendelian Randomization
Collaboration; Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN,
Bowden J, Wade KH, Timpson NJ, Evans DM, et al: Association between
telomere length and risk of cancer and non-neoplastic diseases: A
mendelian randomization study. JAMA Oncol. 3:636–651. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Goh F, Yang IA, Bowman RV and Fong KM:
Subtype variation and actionability of telomere length abnormality
in lung cancer. Transl Lung Cancer Res. 7(Suppl 3): S251–S253.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kachuri L, Latifovic L, Liu G and Hung RJ:
Systematic review of genetic variation in chromosome 5p15.33 and
telomere length as predictive and prognostic biomarkers for lung
cancer. Cancer Epidemiol Biomarkers Prev. 25:1537–1549. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Vaiciulis P, Liutkeviciene R, Liutkevicius
V, Vilkeviciute A, Gedvilaite G and Uloza V: Association of
relative leucocyte telomere length and gene single nucleotide
polymorphisms (TERT, TRF1, TNKS2) in laryngeal squamous cell
carcinoma. Cancer Genomics Proteomics. 17:431–439. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Han P, Dang Z, Shen Z, Dai H, Bai Y, Li B
and Shao Y: Association of SNPs in the OBFC1 gene and laryngeal
carcinoma in Chinese Han male population. Int J Clin Oncol.
24:1042–1048. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lei H, Feng D, Zhou F, Xu H, Tang T, Yu H,
Xie C and Zhou Y: Expression of human protection of telomere 1
correlates with telomere length and radiosensitivity in the human
laryngeal cancer Hep-2 cell line. Oncol Lett. 10:1149–1154. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen W, Xiao BK, Liu JP, Chen SM and Tao
ZZ: Alternative lengthening of telomeres in hTERT-inhibited
laryngeal cancer cells. Cancer Sci. 101:1769–1776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Broberg K, Björk J, Paulsson K, Höglund M
and Albin M: Constitutional short telomeres are strong genetic
susceptibility markers for bladder cancer. Carcinogenesis.
26:1263–1271. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen M, Xu Y, Xu J, Chancoco H and Gu J:
Leukocyte telomere length and bladder cancer risk: A large
case-control study and mendelian randomization analysis. Cancer
Epidemiol Biomarkers Prev. 30:203–209. 2021. View Article : Google Scholar
|
|
65
|
Pavanello S, Carta A, Mastrangelo G,
Campisi M, Arici C and Porru S: Relationship between telomere
length, genetic traits and Environmental/Occupational exposures in
bladder cancer risk by structural equation modelling. Int J Environ
Res Public Health. 15:52017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
McGrath M, Wong JY, Michaud D, Hunter DJ
and De Vivo I: Telomere length, cigarette smoking, and bladder
cancer risk in men and women. Cancer Epidemiol Biomarkers Prev.
16:815–819. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lin J, Blalock JA, Chen M, Ye Y, Gu J,
Cohen L, Cinciripini PM and Wu X: Depressive symptoms and short
telomere length are associated with increased mortality in bladder
cancer patients. Cancer Epidemiol Biomarkers Prev. 24:336–343.
2015. View Article : Google Scholar :
|
|
68
|
Yu C, Hequn C, Longfei L, Long W, Zhi C,
Feng Z, Jinbo C, Chao L and Xiongbing Z: GSTM1 and GSTT1
polymorphisms are associated with increased bladder cancer risk:
Evidence from updated meta-analysis. Oncotarget. 8:3246–3258. 2017.
View Article : Google Scholar :
|
|
69
|
Hosen I, Rachakonda PS, Heidenreich B, de
Verdier PJ, Ryk C, Steineck G, Hemminki K and Kumar R: Mutations in
TERT promoter and FGFR3 and telomere length in bladder cancer. Int
J Cancer. 137:1621–1629. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Fernandez-Gomez J, Escaf Barmadah S,
Gosalbez D, Rodriguez-Faba O, Jalon A, Gonzalez R, Garcia Miralles
T and Calas A: Telomere length on bladder washing samples from
patients with bladder cancer correlates with tumor characteristics
flow cytometry method for quantitative fluorescence in situ
hybridization (flow-FISH technique). Eur Urol. 48:432–437. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang H, Wang Y, Kota KK, Kallakury B,
Mikhail NN, Sayed D, Mokhtar A, Maximous D, Yassin EH, Gouda I, et
al: Strong association between long and heterogeneous telomere
length in blood lymphocytes and bladder cancer risk in Egyptian.
Carcinogenesis. 36:1284–1290. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Gu J, Chen M, Shete S, Amos CI, Kamat A,
Ye Y, Lin J, Dinney CP and Wu X: A genome-wide association study
identifies a locus on chromosome 14q21 as a predictor of leukocyte
telomere length and as a marker of susceptibility for bladder
cancer. Cancer Prev Res (Phila). 4:514–521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Holzmann K, Blin N, Welter C, Zang KD,
Seitz G and Henn W: Telomeric associations and loss of telomeric
DNA repeats in renal tumors. Genes Chromosomes Cancer. 6:178–181.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mehle C, Ljungberg B and Roos G: Telomere
shortening in renal cell carcinoma. Cancer Res. 54:236–241.
1994.PubMed/NCBI
|
|
75
|
Dahse R, Fiedler W, Junker K, Schlichter
A, Schubert J and Claussen U: Telomerase activity and telomere
lengths: Alterations in renal cell carcinomas. Kidney Int.
56:1289–1290. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Pal D, Sharma U, Khajuria R, Singh SK,
Kakkar N and Prasad R: Augmented telomerase activity, reduced
telomere length and the presence of alternative lengthening of
telomere in renal cell carcinoma: Plausible predictive and
diagnostic markers. Gene. 562:145–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Callahan CL, Schwartz K, Ruterbusch JJ,
Shuch B, Graubard BI, Lan Q, Cawthon R, Baccarelli AA, Chow WH,
Rothman N, et al: Leukocyte telomere length and renal cell
carcinoma survival in two studies. Br J Cancer. 117:752–755. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Hofmann JN, Lan Q, Cawthon R, Hosgood HD
III, Shuch B, Moore LE, Rothman N, Chow WH and Purdue MP: A
prospective study of leukocyte telomere length and risk of renal
cell carcinoma. Cancer Epidemiol Biomarkers Prev. 22:997–1000.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Hofmann JN, Baccarelli A, Schwartz K,
Davis FG, Ruterbusch JJ, Hoxha M, McCarthy BJ, Savage SA, Wacholder
S, Rothman N, et al: Risk of renal cell carcinoma in relation to
blood telomere length in a population-based case-control study. Br
J Cancer. 105:1772–1775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Svenson U, Ljungberg B and Roos G:
Telomere length in peripheral blood predicts survival in clear cell
renal cell carcinoma. Cancer Res. 69:2896–2901. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Morais M, Dias F, Teixeira AL and Medeiros
R: Telomere length in renal cell carcinoma: The Jekyll and Hyde
biomarker of ageing of the kidney. Cancer Manag Res. 12:1669–1679.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Machiela MJ, Hofmann JN, Carreras-Torres
R, Brown KM, Johansson M, Wang Z, Foll M, Li P, Rothman N, Savage
SA, et al: Genetic variants related to longer telomere length are
associated with increased risk of renal cell carcinoma. Eur Urol.
72:747–754. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
de Martino M, Taus C, Lucca I, Hofbauer
SL, Haitel A, Shariat SF and Klatte T: Association of human
telomerase reverse transcriptase gene polymorphisms, serum levels,
and telomere length with renal cell carcinoma risk and pathology.
Mol Carcinog. 55:1458–1466. 2016. View Article : Google Scholar
|
|
84
|
Svenson U, Grönlund E, Söderström I,
Sitaram RT, Ljungberg B and Roos G: Telomere length in relation to
immunological parameters in patients with renal cell carcinoma.
PLoS One. 8:e555432013. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Endén K, Tainio J, Hou M, Suominen A,
Pakarinen M, Huang T, Söder O, Jalanko H, Jahnukainen K and
Jahnukainen T: Telomere length regulators are activated in young
men after pediatric kidney transplantation compared to healthy
controls and survivors of childhood cancer-A cross-sectional study.
Pediatr Transplant. 23:e135502019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
HaydeéCottliar AS, Noriega MF, Narbaitz M,
Rodríguez A and Slavutsky IR: Association between telomere length
and BCL2 gene rearrangements in low- and high-grade non-Hodgkin
lymphomas. Cancer Genet Cytogenet. 171:1–8. 2006. View Article : Google Scholar
|
|
87
|
Widmann TA, Herrmann M, Taha N, König J
and Pfreundschuh M: Short telomeres in aggressive non-Hodgkin's
lymphoma as a risk factor in lymphomagenesis. Exp Hematol.
35:939–946. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Lan Q, Cawthon R, Shen M, Weinstein SJ,
Virtamo J, Lim U, Hosgood HD III, Albanes D and Rothman N: A
prospective study of telomere length measured by monochrome
multiplex quantitative PCR and risk of non-Hodgkin lymphoma. Clin
Cancer Res. 15:7429–7433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Machiela MJ, Lan Q, Slager SL, Vermeulen
RC, Teras LR, Camp NJ, Cerhan JR, Spinelli JJ, Wang SS, Nieters A,
et al: Genetically predicted longer telomere length is associated
with increased risk of B-cell lymphoma subtypes. Hum Mol Genet.
25:1663–1676. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Lee JJ, Nam CE, Cho SH, Park KS, Chung IJ
and Kim HJ: Telomere length shortening in non-Hodgkin's lymphoma
patients undergoing chemotherapy. Ann Hematol. 82:492–495. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Remes K, Norrback KF, Rosenquist R, Mehle
C, Lindh J and Roos G: Telomere length and telomerase activity in
malignant lymphomas at diagnosis and relapse. Br J Cancer.
82:601–607. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Adamson DJ, King DJ and Haites NE:
Significant telomere shortening in childhood leukemia. Cancer Genet
Cytogenet. 61:204–206. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Engelhardt M, Ozkaynak MF, Drullinsky P,
Sandoval C, Tugal O, Jayabose S and Moore MA: Telomerase activity
and telomere length in pediatric patients with malignancies
undergoing chemotherapy. Leukemia. 12:13–24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Borssén M, Cullman I, Norén-Nyström U,
Sundström C, Porwit A, Forestier E and Roos G: hTERT promoter
methylation and telomere length in childhood acute lymphoblastic
leukemia: Associations with immunophenotype and cytogenetic
subgroup. Exp Hematol. 39:1144–1151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Wang Y, Fang M, Sun X and Sun J:
Telomerase activity and telomere length in acute leukemia:
Correlations with disease progression, subtypes and overall
survival. Int J Lab Hematol. 32:230–238. 2010. View Article : Google Scholar
|
|
96
|
Eskandari E, Hashemi M, Naderi M, Bahari
G, Safdari V and Taheri M: Leukocyte telomere length shortening,
hTERT genetic polymorphisms and risk of childhood acute
lymphoblastic leukemia. Asian Pac J Cancer Prev. 19:1515–1521.
2018.PubMed/NCBI
|
|
97
|
Sheng X, Zhang L, Luo D, Tong N, Wang M,
Fang Y, Li J and Zhang Z: A common variant near TERC and telomere
length are associated with susceptibility to childhood acute
lymphoblastic leukemia in Chinese. Leuk Lymphoma. 53:1688–1692.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Takauchi K, Tashiro S, Ohtaki M and Kamada
N: Telomere reduction of specific chromosome translocation in acute
myelocytic leukemia. Jpn J Cancer Res. 85:127–130. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Sieglová Z, Zilovcová S, Cermák J, Ríhová
H, Brezinová D, Dvoráková R, Marková M, Maaloufová J, Sajdová J,
Brezinová J, et al: Dynamics of telomere erosion and its
association with genome instability in myelodysplastic syndromes
(MDS) and acute myelogenous leukemia arising from MDS: A marker of
disease prognosis? Leuk Res. 28:1013–1021. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Lansdorp PM: Maintenance of telomere
length in AML. Blood Adv. 1:2467–2472. 2017. View Article : Google Scholar
|
|
101
|
Wang Y, Wang T, Dagnall C, Haagenson M,
Spellman SR, Hicks B, Jones K, Lee SJ, Savage SA and Gadalla SM:
Relative telomere length before hematopoietic cell transplantation
and outcome after unrelated donor hematopoietic cell
transplantation for acute leukemia. Biol Blood Marrow Transplant.
23:1054–1058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Swiggers SJ, Kuijpers MA, de Cort MJ,
Beverloo HB and Zijlmans JM: Critically short telomeres in acute
myeloid leukemia with loss or gain of parts of chromosomes. Genes
Chromosomes Cancer. 45:247–256. 2006. View Article : Google Scholar
|
|
103
|
Behrens YL, Thomay K, Hagedorn M, Ebersold
J, Schmidt G, Lentes J, Davenport C, Schlegelberger B and Göhring
G: Jumping translocations: Short telomeres or pathogenic TP53
variants as underlying mechanism in acute myeloid leukemia and
myelodysplastic syndrome? Genes Chromosomes Cancer. 58:139–148.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Watts JM, Dumitriu B, Hilden P, Kishtagari
A, Rapaport F, Chen C, Ahn J, Devlin SM, Stein EM, Rampal R, et al:
Telomere length and associations with somatic mutations and
clinical outcomes in acute myeloid leukemia. Leuk Res. 49:62–65.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li AM, Hyagu S, Maze D, Schreiber R, Sirrs
S, Stockler-Ipsiroglu S, Sutherland H, Vercauteren S and Schultz
KR: Prolonged granulocyte colony stimulating factor use in glycogen
storage disease type 1b associated with acute myeloid leukemia and
with shortened telomere length. Pediatr Hematol Oncol. 35:45–51.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Aalbers AM, Calado RT, Young NS, Zwaan CM,
Wu C, Kajigaya S, Coenen EA, Baruchel A, Geleijns K, de Haas V, et
al: Telomere length and telomerase complex mutations in pediatric
acute myeloid leukemia. Leukemia. 27:1786–1789. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Song DY, Kim JA, Jeong D, Yun J, Kim SM,
Lim K, Park SN, Im K, Choi S, Yoon SS and Lee DS: Telomere length
and its correlation with gene mutations in chronic lymphocytic
leukemia in a Korean population. PLoS One. 14:e02201772019.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Jebaraj BMC, Tausch E, Landau DA, Bahlo J,
Robrecht S, Taylor-Weiner AN, Bloehdorn J, Scheffold A, Mertens D,
Böttcher S, et al: Short telomeres are associated with inferior
outcome, genomic complexity, and clonal evolution in chronic
lymphocytic leukemia. Leukemia. 33:2183–2194. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Thomay K, Fedder C, Hofmann W, Kreipe H,
Stadler M, Titgemeyer J, Zander I, Schlegelberger B and Göhring G:
Telomere shortening, TP53 mutations and deletions in chronic
lymphocytic leukemia result in increased chromosomal instability
and breakpoint clustering in heterochromatic regions. Ann Hematol.
96:1493–1500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Steinbrecher D, Jebaraj BMC, Schneider C,
Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E,
Scheffold A, et al: Telomere length in poor-risk chronic
lymphocytic leukemia: Associations with disease characteristics and
outcome. Leuk Lymphoma. 59:1614–1623. 2018. View Article : Google Scholar
|
|
111
|
Strefford JC, Kadalayil L, Forster J,
Rose-Zerilli MJ, Parker A, Lin TT, Heppel N, Norris K, Gardiner A,
Davies Z, et al: Telomere length predicts progression and overall
survival in chronic lymphocytic leukemia: Data from the UK LRF CLL4
trial. Leukemia. 29:2411–2414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Dos Santos P, Panero J, Palau Nagore V,
Stanganelli C, Bezares RF and Slavutsky I: Telomere shortening
associated with increased genomic complexity in chronic lymphocytic
leukemia. Tumour Biol. 36:8317–8324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Palma M, Parker A, Hojjat-Farsangi M,
Forster J, Kokhaei P, Hansson L, Osterborg A and Mellstedt H:
Telomere length and expression of human telomerase reverse
transcriptase splice variants in chronic lymphocytic leukemia. Exp
Hematol. 41:615–626. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Sellmann L, de Beer D, Bartels M, Opalka
B, Nückel H, Dührsen U, Dürig J, Seifert M, Siemer D, Küppers R, et
al: Telomeres and prognosis in patients with chronic lymphocytic
leukaemia. Int J Hematol. 93:74–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Roos G, Kröber A, Grabowski P, Kienle D,
Bühler A, Döhner H, Rosenquist R and Stilgenbauer S: Short
telomeres are associated with genetic complexity, high-risk genomic
aberrations, and short survival in chronic lymphocytic leukemia.
Blood. 111:2246–2252. 2008. View Article : Google Scholar
|
|
116
|
Lin TT, Letsolo BT, Jones RE, Rowson J,
Pratt G, Hewamana S, Fegan C, Pepper C and Baird DM: Telomere
dysfunction and fusion during the progression of chronic
lymphocytic leukemia: Evidence for a telomere crisis. Blood.
116:1899–1907. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Ojha J, Codd V, Nelson CP, Samani NJ,
Smirnov IV, Madsen NR, Hansen HM, de Smith AJ, Bracci PM, Wiencke
JK, et al: ENGAGE Consortium Telomere Group. Genetic variation
associated with longer telomere length increases risk of chronic
lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev.
25:1043–1049. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wysoczanska B, Dratwa M, Gebura K, Mizgala
J, Mazur G, Wrobel T and Bogunia-Kubik K: Variability within the
human TERT gene, telomere length and predisposition to chronic
lymphocytic leukemia. Onco Targets Ther. 12:4309–4320. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Furtado FM, Scheucher PS, Santana BA,
Scatena NF, Calado RT, Rego EM, Matos DM and Falcão RP: Telomere
length analysis in monoclonal B-cell lymphocytosis and chronic
lymphocytic leukemia Binet A. Braz J Med Biol Res. 50:e60192017.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Yang L, Kost SEF, Beiggi S, Zhang Y,
Schmidt R, Nugent Z, Marshall A, Banerji V, Gibson SB and Johnston
JB: Buccal cell telomere length is not a useful marker for
comorbidities in chronic lymphocytic leukemia. Leuk Res.
86:1062202019. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Kaifie A, Schikowsky C, Vasko T, Kraus T,
Brümmendorf TH and Ziegler P: Additional benefits of telomere
length (TL) measurements in chronic lymphocytic leukemia. Leuk
Lymphoma. 60:541–543. 2019. View Article : Google Scholar
|
|
122
|
Iwama H, Ohyashiki K, Ohyashiki JH,
Hayashi S, Kawakubo K, Shay JW and Toyama K: The relationship
between telomere length and therapy-associated cytogenetic
responses in patients with chronic myeloid leukemia. Cancer.
79:1552–1560. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Brümmendorf TH, Holyoake TL, Rufer N,
Barnett MJ, Schulzer M, Eaves CJ, Eaves AC and Lansdorp PM:
Prognostic implications of differences in telomere length between
normal and malignant cells from patients with chronic myeloid
leukemia measured by flow cytometry. Blood. 95:1883–1890. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Bouillon AS, Ventura Ferreira MS, Awad SA,
Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J,
Ossenkoppele G, Westerweel PE, et al: Telomere shortening
correlates with leukemic stem cell burden at diagnosis of chronic
myeloid leukemia. Blood Adv. 2:1572–1579. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Boultwood J, Fidler C, Shepherd P, Watkins
F, Snowball J, Haynes S, Kusec R, Gaiger A, Littlewood TJ, Peniket
AJ and Wainscoat JS: Telomere length shortening is associated with
disease evolution in chronic myelogenous leukemia. Am J Hematol.
61:5–9. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Drummond M, Lennard A, Brûmmendorf T and
Holyoake T: Telomere shortening correlates with prognostic score at
diagnosis and proceeds rapidly during progression of chronic
myeloid leukemia. Leuk Lymphoma. 45:1775–1781. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Keller G, Brassat U, Braig M, Heim D, Wege
H and Brümmendorf TH: Telomeres and telomerase in chronic myeloid
leukaemia: Impact for pathogenesis, disease progression and
targeted therapy. Hematol Oncol. 27:123–129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Boultwood J, Peniket A, Watkins F,
Shepherd P, McGale P, Richards S, Fidler C, Littlewood TJ and
Wainscoat JS: Telomere length shortening in chronic myelogenous
leukemia is associated with reduced time to accelerated phase.
Blood. 96:358–361. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Caocci G, Greco M, Delogu G, Secchi C,
Martino B, Labate C, Abruzzese E, Trawinska MM, Galimberti S, Orru
F, et al: Telomere length shortening is associated with
treatment-free remission in chronic myeloid leukemia patients. J
Hematol Oncol. 9:632016. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Samassekou O, Ntwari A, Hébert J and Yan
J: Individual telomere lengths in chronic myeloid leukemia.
Neoplasia. 11:1146–1154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Nikolouzakis TK, Falzone L, Lasithiotakis
K, Krüger-Krasagakis S, Kalogeraki A, Sifaki M, Spandidos DA,
Chrysos E, Tsatsakis A and Tsiaoussis J: Current and future trends
in molecular biomarkers for diagnostic, prognostic, and predictive
purposes in non-melanoma skin cancer. J Clin Med. 9:28682020.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Llorca-Cardeñosa MJ, Peña-Chilet M, Mayor
M, Gomez-Fernandez C, Casado B, Martin-Gonzalez M, Carretero G,
Lluch A, Martinez-Cadenas C, Ibarrola-Villava M and Ribas G: Long
telomere length and a TERT-CLPTM1 locus polymorphism association
with melanoma risk. Eur J Cancer. 50:3168–3177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Anic GM, Sondak VK, Messina JL, Fenske NA,
Zager JS, Cherpelis BS, Lee JH, Fulp WJ, Epling-Burnette PK, Park
JY and Rollison DE: Telomere length and risk of melanoma, squamous
cell carcinoma, and basal cell carcinoma. Cancer Epidemiol.
37:434–439. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Bodelon C, Pfeiffer RM, Bollati V,
Debbache J, Calista D, Ghiorzo P, Fargnoli MC, Bianchi-Scarra G,
Peris K, Hoxha M, et al: On the interplay of telomeres, nevi and
the risk of melanoma. PLoS One. 7:e524662012. View Article : Google Scholar
|
|
135
|
Han J, Qureshi AA, Prescott J, Guo Q, Ye
L, Hunter DJ and De Vivo I: A prospective study of telomere length
and the risk of skin cancer. J Invest Dermatol. 129:415–421. 2009.
View Article : Google Scholar :
|
|
136
|
Nan H, Du M, De Vivo I, Manson JE, Liu S,
McTiernan A, Curb JD, Lessin LS, Bonner MR, Guo Q, et al: Shorter
telomeres associate with a reduced risk of melanoma development.
Cancer Res. 71:6758–6763. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Burke LS, Hyland PL, Pfeiffer RM, Prescott
J, Wheeler W, Mirabello L, Savage SA, Burdette L, Yeager M, Chanock
S, et al: Telomere length and the risk of cutaneous malignant
melanoma in melanoma-prone families with and without CDKN2A
mutations. PLoS One. 8:711212013. View Article : Google Scholar
|
|
138
|
Caini S, Raimondi S, Johansson H, De
Giorgi V, Zanna I, Palli D and Gandini S: Telomere length and the
risk of cutaneous melanoma and non-melanoma skin cancer: A review
of the literature and meta-analysis. J Dermatol Sci. 80:168–174.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Rachakonda S, Srinivas N, Mahmoudpour SH,
Garcia-Casado Z, Requena C, Traves V, Soriano V, Cardelli M,
Pjanova D, Molven A, et al: Telomere length and survival in primary
cutaneous melanoma patients. Sci Rep. 8:109472018. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Viceconte N, Dheur MS, Majerova E,
Pierreux CE, Baurain JF, van Baren N and Decottignies A: Highly
aggressive metastatic melanoma cells unable to maintain telomere
length. Cell Rep. 19:2529–2543. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Menin C, Bojnik E, Del Bianco P, Elefanti
L, Gianesin K, Keppel S, Stagni C, Mocellin S, Vecchiato A and De
Rossi A: Differences in telomere length between sporadic and
familial cutaneous melanoma. Br J Dermatol. 175:937–943. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Kammori M, Takubo K, Nakamura K, Furugouri
E, Endo H, Kanauchi H, Mimura Y and Kaminishi M: Telomerase
activity and telomere length in benign and malignant human thyroid
tissues. Cancer Lett. 159:175–181. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Matthews P, Jones CJ, Skinner J, Haughton
M, de Micco C and Wynford-Thomas D: Telomerase activity and
telomere length in thyroid neoplasia: Biological and clinical
implications. J Pathol. 194:183–193. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Dong C and Hemminki K: Modification of
cancer risks in offspring by sibling and parental cancers from
2,112,616 nuclear families. Int J Cancer. 92:144–150. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Jendrzejewski J, Tomsic J, Lozanski G,
Labanowska J, He H, Liyanarachchi S, Nagy R, Ringel MD, Kloos RT,
Heerema NA and de la Chapelle A: Telomere length and telomerase
reverse transcriptase gene copy number in patients with papillary
thyroid carcinoma. J Clin Endocrinol Metab. 96:1876–1880. 2011.
View Article : Google Scholar
|
|
146
|
Capezzone M, Cantara S, Marchisotta S,
Filetti S, De Santi MM, Rossi B, Ronga G, Durante C and Pacini F:
Short telomeres, telomerase reverse transcriptase gene
amplification, and increased telomerase activity in the blood of
familial papillary thyroid cancer patients. J Clin Endocrinol
Metab. 93:3950–3957. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Capezzone M, Cantara S, Marchisotta S,
Busonero G, Formichi C, Benigni M, Capuano S, Toti P,
Pazaitou-Panayiotou K, Caruso G, et al: Telomere length in
neoplastic and nonneoplastic tissues of patients with familial and
sporadic papillary thyroid cancer. J Clin Endocrinol Metab.
96:1852–1856. 2011. View Article : Google Scholar
|
|
148
|
He M, Bian B, Gesuwan K, Gulati N, Zhang
L, Nilubol N and Kebebew E: Telomere length is shorter in affected
members of families with familial nonmedullary thyroid cancer.
Thyroid. 23:301–307. 2013. View Article : Google Scholar :
|
|
149
|
Gramatges MM, Morton LM, Yasui Y, Arnold
MA, Neglia JP, Leisenring WM, Machiela MJ, Dagnall CL, Chanock SJ,
Armstrong GT, et al: Telomere length-associated genetic variants
and the risk of thyroid cancer in survivors of childhood cancer: A
report from the childhood cancer survivor study (CCSS). Cancer
Epidemiol Biomarkers Prev. 28:417–419. 2019. View Article : Google Scholar :
|
|
150
|
Li J, An C, Zheng H, Lei T, Zhang N, Zheng
Y and Yang M: Leukocyte telomere length and risk of papillary
thyroid carcinoma. J Clin Endocrinol Metab. 104:2712–2718. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Graham MK and Meeker A: Telomeres and
telomerase in prostate cancer development and therapy. Nat Rev
Urol. 14:607–619. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Xu J, Chang WS, Tsai CW, Bau DT, Xu Y,
Davis JW, Thompson TC, Logothetis CJ and Gu J: Leukocyte telomere
length is associated with aggressive prostate cancer in localized
prostate cancer patients. EBioMedicine. 52:1026162020. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Tsai CW, Chang WS, Xu J, Xu Y, Huang M,
Pettaway C, Bau DT and Gu J: Leukocyte telomere length is
associated with aggressive prostate cancer in localized African
American prostate cancer patients. Carcinogenesis. 41:1213–1218.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Hu R, Hua XG and Jiang QC: Associations of
telomere length in risk and recurrence of prostate cancer: A
meta-analysis. Andrologia. 51:e133042019. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Luxton JJ, McKenna MJ, Lewis AM, Taylor
LE, Jhavar SG, Swanson GP and Bailey SM: Telomere length dynamics
and chromosomal instability for predicting individual
radiosensitivity and risk via machine learning. J Pers Med.
11:1882021. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Gu CY, Jin SM, Qin XJ, Zhu Y, Bo D, Lin
GW, Shi GH and Ye DW: Genetic variants in RTEL1 influencing
telomere length are associated with prostate cancer risk. J Cancer.
10:6170–6174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Hurwitz LM, Heaphy CM, Joshu CE, Isaacs
WB, Konishi Y, De Marzo AM, Isaacs SD, Wiley KE, Platz EA and
Meeker AK: Telomere length as a risk factor for hereditary prostate
cancer. Prostate. 74:359–364. 2014. View Article : Google Scholar
|
|
158
|
Julin B, Shui I, Heaphy CM, Joshu CE,
Meeker AK, Giovannucci E, De Vivo I and Platz EA: Circulating
leukocyte telomere length and risk of overall and aggressive
prostate cancer. Br J Cancer. 112:769–776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Renner W, Krenn-Pilko S, Gruber HJ,
Herrmann M and Langsenlehner T: Relative telomere length and
prostate cancer mortality. Prostate Cancer Prostatic Dis.
21:579–583. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Svenson U, Roos G and Wikström P: Long
leukocyte telomere length in prostate cancer patients at diagnosis
is associated with poor metastasis-free and cancer-specific
survival. Tumour Biol. 39:10104283176922362017. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Wulaningsih W, Astuti Y, Matsuguchi T,
Anggrandariyanny P and Watkins J; PILAR Research Network:
Circulating Prostate-specific antigen and telomere length in a
nationally representative sample of men without history of prostate
cancer. Prostate. 77:22–32. 2017. View Article : Google Scholar
|
|
162
|
Heaphy CM, Haffner MC, Graham MK, Lim D,
Davis C, Corey E, Epstein JI, Eisenberger MA, Wang H, De Marzo AM,
et al: Telomere lengths differ significantly between small-cell
neuroendocrine prostate carcinoma and adenocarcinoma of the
prostate. Hum Pathol. 101:70–79. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Mirabello L, Huang WY, Wong JY, Chatterjee
N, Reding D, Crawford ED, De Vivo I, Hayes RB and Savage SA: The
association between leukocyte telomere length and cigarette
smoking, dietary and physical variables, and risk of prostate
cancer. Aging Cell. 8:405–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Joshu CE, Peskoe SB, Heaphy CM, Kenfield
SA, Mucci LA, Giovannucci EL, Stampfer MJ, Yoon G, Lee TK, Hicks
JL, et al: Current or recent smoking is associated with more
variable telomere length in prostate stromal cells and prostate
cancer cells. Prostate. 78:233–238. 2018. View Article : Google Scholar :
|
|
165
|
Heaphy CM, Joshu CE, Barber JR, Davis C,
Zarinshenas R, De Marzo AM, Lotan TL, Sfanos KS, Meeker AK, Platz
EA, et al: Racial difference in prostate cancer cell telomere
lengths in men with higher grade prostate cancer: A clue to the
racial disparity in prostate cancer outcomes. Cancer Epidemiol
Biomarkers Prev. 29:676–680. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Luu HN, Long J, Wen W, Zheng Y, Cai Q, Gao
YT, Zheng W and Shu XO: Association between genetic risk score for
telomere length and risk of breast cancer. Cancer Causes Control.
27:1219–1228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Kroupa M, Rachakonda S, Vymetalkova V,
Tomasova K, Liska V, Vodenkova S, Cumova A, Rossnerova A, Vodickova
L, Hemminki K, et al: Telomere length in peripheral blood
lymphocytes related to genetic variation in telomerase, prognosis
and clinicopathological features in breast cancer patients.
Mutagenesis. 35:491–497. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Samavat H, Xun X, Jin A, Wang R, Koh WP
and Yuan JM: Association between prediagnostic leukocyte telomere
length and breast cancer risk: The Singapore Chinese Health Study.
Breast Cancer Res. 21:502019. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Pellatt AJ, Wolff RK, Torres-Mejia G, John
EM, Herrick JS, Lundgreen A, Baumgartner KB, Giuliano AR, Hines LM,
Fejerman L, et al: Telomere length, telomere-related genes, and
breast cancer risk: The breast cancer health disparities study.
Genes Chromosomes Cancer. 52:595–609. 2013.PubMed/NCBI
|
|
170
|
Wang Z, Zhang Z, Guo Y, Shui H, Liu G, Jin
T and Wang H: Shorter telomere length is associated with increased
breast cancer risk in a Chinese Han population: A Case-Control
analysis. J Breast Cancer. 21:391–398. 2018. View Article : Google Scholar
|
|
171
|
Shen J, Terry MB, Gurvich I, Liao Y, Senie
RT and Santella RM: Short telomere length and breast cancer risk: A
study in sister sets. Cancer Res. 67:5538–5544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Pavanello S, Varesco L, Gismondi V, Bruzzi
P and Bolognesi C: Leucocytes telomere length and breast cancer
risk/susceptibility: A case-control study. PLoS One.
13:e01975222018. View Article : Google Scholar
|
|
173
|
Duggan C, Risques R, Alfano C, Prunkard D,
Imayama I, Holte S, Baumgartner K, Baumgartner R, Bernstein L,
Ballard-Barbash R, et al: Change in peripheral blood leukocyte
telomere length and mortality in breast cancer survivors. J Natl
Cancer Inst. 106:dju0352014. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Ceja-Rangel HA, Sánchez-Suárez P,
Castellanos-Juárez E, Peñaroja-Flores R, Arenas-Aranda DJ, Gariglio
P and Benítez-Bribiesca L: Shorter telomeres and high telomerase
activity correlate with a highly aggressive phenotype in breast
cancer cell lines. Tumour Biol. 37:11917–11926. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Kammori M, Sugishita Y, Okamoto T,
Kobayashi M, Yamazaki K, Yamada E and Yamada T: Telomere shortening
in breast cancer correlates with the pathological features of tumor
progression. Oncol Rep. 34:627–632. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Barczak W, Rozwadowska N, Romaniuk A,
Lipińska N, Lisiak N, Grodecka-Gazdecka S, Książek K and Rubiś B:
Telomere length assessment in leukocytes presents potential
diagnostic value in patients with breast cancer. Oncol Lett.
11:2305–2309. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Eyüboğlu İP, Yenmiş G, Bingöl EN, Yüksel
Ş, Tokat F, Özbek P, Güllü Amuran G, Yakıcıer C and Akkiprik M:
Next-generation sequencing identifies BRCA1 and/or BRCA2 mutations
in Women at high hereditary risk for breast cancer with shorter
telomere length. OMICS. 24:5–15. 2020. View Article : Google Scholar
|
|
178
|
Badie S, Escandell JM, Bouwman P, Carlos
AR, Thanasoula M, Gallardo MM, Suram A, Jaco I, Benitez J, Herbig
U, et al: BRCA2 acts as a RAD51 loader to facilitate telomere
replication and capping. Nat Struct Mol Biol. 17:1461–1469. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Thorvaldsdottir B, Aradottir M, Stefansson
OA, Bodvarsdottir SK and Eyfjörd JE: Telomere length is predictive
of breast cancer risk in BRCA2 mutation carriers. Cancer Epidemiol
Biomarkers Prev. 26:1248–1254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Ennour-Idrissi K, Maunsell E and Diorio C:
Telomere length and breast cancer prognosis: A systematic review.
Cancer Epidemiol Biomarkers Prev. 26:3–10. 2017. View Article : Google Scholar
|
|
181
|
Garland SN, Johnson B, Palmer C, Speck RM,
Donelson M, Xie SX, DeMichele A and Mao JJ: Physical activity and
telomere length in early stage breast cancer survivors. Breast
Cancer Res. 16:4132014. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Alhareeri AA, Archer KJ, Fu H, Lyon DE,
Elswick RK Jr, Kelly DL, Starkweather AR, Elmore LW, Bokhari YA and
Jackson-Cook CK: Telomere lengths in women treated for breast
cancer show associations with chemotherapy, pain symptoms, and
cognitive domain measures: A longitudinal study. Breast Cancer Res.
22:1372020. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Mirabello L, Garcia-Closas M, Cawthon R,
Lissowska J, Brinton LA, Pepłońska B, Sherman ME and Savage SA:
Leukocyte telomere length in a population-based case-control study
of ovarian cancer: A pilot study. Cancer Causes Control. 21:77–82.
2010. View Article : Google Scholar
|
|
184
|
Kuhn E, Meeker AK, Visvanathan K, Gross
AL, Wang TL, Kurman RJ and Shih IeM: Telomere length in different
histologic types of ovarian carcinoma with emphasis on clear cell
carcinoma. Mod Pathol. 24:1139–1145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Vajpeyi R: WHO Classification of Tumours:
Pathology and genetics of tumours of the breast and female genital
organs. J Clin Pathol. 58:671–672. 2005.
|
|
186
|
Martinez-Delgado B, Anowsky K,
Inglada-Perez L, de la Hoya M, Caldes T, Vega A, Blanco A, Martin
T, Gonzalez-Sarmiento R, Blasco M, et al: Shorter telomere length
is associated with increased ovarian cancer risk in both familial
and sporadic cases. J Med Genet. 49:341–344. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Falandry C, Horard B, Bruyas A, Legouffe
E, Cretin J, Meunier J, Alexandre J, Delecroix V, Fabbro M, Certain
MN, et al: Telomere length is a prognostic biomarker in elderly
advanced ovarian cancer patients: A multicenter GINECO study. Aging
(Albany NY). 7:1066–1076. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Yang M, Prescott J, Poole EM, Rice MS,
Kubzansky LD, Idahl A, Lundin E, De Vivo I and Tworoger SS:
Prediagnosis leukocyte telomere length and risk of ovarian cancer.
Cancer Epidemiol Biomarkers Prev. 26:339–345. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Bojesen SE, Pooley KA, Johnatty SE,
Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen
HC, Smart CE, et al: Multiple independent variants at the TERT
locus are associated with telomere length and risks of breast and
ovarian cancer. Nat Genet. 45:371–384. 384e1–2. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Terry KL, Tworoger SS, Vitonis AF, Wong J,
Titus-Ernstoff L, De Vivo I and Cramer DW: Telomere length and
genetic variation in telomere maintenance genes in relation to
ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 21:504–512.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Kotsopoulos J, Prescott J, De Vivo I, Fan
I, Mclaughlin J, Rosen B, Risch H, Sun P and Narod SA: Telomere
length and mortality following a diagnosis of ovarian cancer.
Cancer Epidemiol Biomarkers Prev. 23:2603–2606. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Antoun S, Atallah D, Tahtouh R, Assaf MD,
Moubarak M, Ayoub EN, Chahine G and Hilal G: Glucose restriction
combined with chemotherapy decreases telomere length and cancer
antigen-125 secretion in ovarian carcinoma. Oncol Lett.
19:1338–1350. 2020.PubMed/NCBI
|
|
193
|
Victorelli S and Passos JF: Telomeres and
cell senescence-size matters not. EBioMedicine. 21:14–20. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Kim B, Ryu KJ, Lee S and Kim T: Changes in
telomere length and senescence markers during human ovarian tissue
cryopreservation. Sci Rep. 11:22382021. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Zhang DK, Ngan HY, Cheng RY, Cheung AN,
Liu SS and Tsao SW: Clinical significance of telomerase activation
and telomeric restriction fragment (TRF) in cervical cancer. Eur J
Cancer. 35:154–160. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Maida Y, Kyo S, Forsyth NR, Takakura M,
Sakaguchi J, Mizumoto Y, Hashimoto M, Nakamura M, Nakao S and Inoue
M: Distinct telomere length regulation in premalignant cervical and
endometrial lesions: Implications for the roles of telomeres in
uterine carcinogenesis. J Pathol. 210:214–223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Chen X, Wei S, Ma H, Jin G, Hu Z, Suping
H, Li D, Hang D, Wu X and Li N: Telomere length in cervical
exfoliated cells, interaction with HPV genotype, and cervical
cancer occurrence among high-risk HPV-positive women. Cancer Me.
8:4845–4851. 2019. View Article : Google Scholar
|
|
198
|
Azzalin CM, Reichenbach P, Khoriauli L,
Giulotto E and Lingner J: Telomeric repeat containing RNA and RNA
surveillance factors at mammalian chromosome ends. Science.
318:798–801. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Deng Z, Wang Z, Xiang C, Molczan A, Baubet
V, Conejo-Garcia J, Xu X, Lieberman PM and Dahmane N: Formation of
telomeric repeat-containing RNA (TERRA) foci in highly
proliferating mouse cerebellar neuronal progenitors and
medulloblastoma. J Cell Sci. 125:4383–4394. 2012.PubMed/NCBI
|
|
200
|
Oh BK, Keo P, Bae J, Ko JH and Choi JS:
Variable TERRA abundance and stability in cervical cancer cells.
Int J Mol Med. 39:1597–1604. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Déjardin J and Kingston RE: Purification
of proteins associated with specific genomic Loci. Cell.
136:175–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Kappei D, Butter F, Benda C, Scheibe M,
Draškovič I, Stevense M, Novo CL, Basquin C, Araki M, Krastev DB,
et al: HOT1 is a mammalian direct telomere repeat-binding protein
contributing to telomerase recruitment. EMBO J. 32:1681–1701. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Zhou S, Xiao Y, Zhuang Y, Liu Y, Zhao H,
Yang H, Xie C, Zhou F and Zhou Y: Knockdown of homeobox containing
1 increases the radiosensitivity of cervical cancer cells through
telomere shortening. Oncol Rep. 38:515–521. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Du J, Xue W, Ji Y, Zhu X, Gu Y, Zhu M,
Wang C, Gao Y, Dai J, Ma H, et al: U-shaped association between
telomere length and esophageal squamous cell carcinoma risk: A
case-control study in Chinese population. Front Med. 9:478–486.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Xing J, Ajani JA, Chen M, Izzo J, Lin J,
Chen Z, Gu J and Wu X: Constitutive short telomere length of
chromosome 17p and 12q but not 11q and 2p is associated with an
increased risk for esophageal cancer. Cancer Prev Res (Phila).
2:459–465. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Zheng YL, Hu N, Sun Q, Wang C and Taylor
PR: Telomere attrition in cancer cells and telomere length in tumor
stroma cells predict chromosome instability in esophagealsquamous
cell carcinoma: A genome-wide analysis. Cancer Res. 69:1604–1614.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Lin SW, Abnet CC, Freedman ND, Murphy G,
Risques R, Prunkard D, Rabinovitch P, Pan QJ, Roth MJ, Wang GQ, et
al: Measuring telomere length for the early detection of precursor
lesions of esophageal squamous cell carcinoma. BMC Cancer.
13:5782013. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Li Z, Song Y, Xu Y, Shen Y, Zhang N, Yang
M and Yu D: Identification of Leukocyte telomere length-related
genetic variants contributing to predisposition of Esophageal
Squamous Cell Carcinoma. J Cancer. 11:5025–5031. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Lu Y, Yan C, Du J, Ji Y, Gao Y, Zhu X, Yu
F, Huang T, Dai J, Ma H, et al: Genetic variants affecting telomere
length are associated with the prognosis of esophageal squamous
cell carcinoma in a Chinese population. Mol Carcinog. 56:1021–1029.
2017. View Article : Google Scholar
|
|
210
|
Shi J, Sun F, Peng L, Li B, Liu L, Zhou C,
Han J, Zhang L, Zhou L, Zhang X, et al: Leukocyte telomere
length-related genetic variants in 1p34.2 and 14q21 loci contribute
to the risk of esophageal squamous cell carcinoma. Int J Cancer.
132:2799–2807. 2013. View Article : Google Scholar
|
|
211
|
Hao XD, Yang Y, Song X, Zhao XK, Wang LD,
He JD, Kong QP, Tang NL and Zhang YP: Correlation of telomere
length shortening with TP53 somatic mutations, polymorphisms and
allelic loss in breast tumors and esophageal cancer. Oncol Rep.
29:226–236. 2013. View Article : Google Scholar
|
|
212
|
Yu Q, Yang J, Liu B, Li W, Hu G, Qiu H,
Huang L, Xiong H and Yuan X: Combined effects of leukocyte telomere
length, p53 polymorphism and human papillomavirus infection on
esophageal squamous cell carcinoma in a Han Chinese population.
Cancer Epidemiol. 38:569–575. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Wennerström EC, Risques RA, Prunkard D,
Giffen C, Corley DA, Murray LJ, Whiteman DC, Wu AH, Bernstein L, Ye
W, et al: Leukocyte telomere length in relation to the risk of
Barrett's esophagus and esophageal adenocarcinoma. Cancer Med.
5:2657–2665. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Pan W, Du J, Shi M, Jin G and Yang M:
Short leukocyte telomere length, alone and in combination with
smoking, contributes to increased risk of gastric cancer or
esophageal squamous cell carcinoma. Carcinogenesis. 38:12–18. 2017.
View Article : Google Scholar
|
|
215
|
Tahara T, Tahara S, Horiguchi N, Kawamura
T, Okubo M, Ishizuka T, Yamada H, Yoshida D, Ohmori T, Maeda K, et
al: Telomere length in leukocyte DNA in gastric cancer patients and
its association with Clinicopathological features and prognosis.
Anticancer Res. 37:1997–2001. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Hou L, Savage SA, Blaser MJ, Perez-Perez
G, Hoxha M, Dioni L, Pegoraro V, Dong LM, Zatonski W, Lissowska J,
et al: Telomere length in peripheral leukocyte DNA and gastric
cancer risk. Cancer Epidemiol Biomarkers Prev. 18:3103–3109. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Qu F, Li R, He X, Li Q, Xie S, Gong L, Ji
G, Lu J and Bao G: Short telomere length in peripheral blood
leukocytes predicts poor prognosis and indicates an
immunosuppressive phenotypegastric cancer patients. Mol Oncol.
9:727–739. 2015. View Article : Google Scholar
|
|
218
|
Wang Z, Koh WP, Jin A, Wang R and Yuan JM:
Telomere length and risk of developing gastric adenocarcinoma: The
Singapore Chinese Health Study. Gastric Cancer. 2:598–605. 2018.
View Article : Google Scholar
|
|
219
|
Weischer M, Nordestgaard BG, Cawthon RM,
Freiberg JJ, Tybjærg-Hansen A and Bojesen SE: Short telomere
length, cancer survival, and cancer risk in 47102 individuals. J
Natl Cancer Inst. 105:459–468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Liu X, Bao G, Huo T, Wang Z, He X and Dong
G: Constitutive telomere length and gastric cancer risk:
Case-control analysis in Chinese Han population. Cancer Sci.
100:1300–1305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Liu Y, Lei T, Zhang N, Zheng Y, Kou P,
Shang S and Yang M: Leukocyte telomere length and risk of gastric
cardia adenocarcinoma. Sci Rep. 8:145842018. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Tahara T, Shibata T, Kawamura T, Horiguchi
N, Okubo M, Nakano N, Ishizuka T, Nagasaka M, Nakagawa Y and Ohmiya
N: Telomere length shortening in gastric mucosa is a field effect
associated with increased risk of gastric cancer. Virchows Arch.
469:19–24. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Heo YR and Lee JH: Association between
telomere length and PIK3CA amplification in gastric cancer. Clin
Exp Med. 18:133–134. 2018. View Article : Google Scholar
|
|
224
|
Lili M, Yuxiang F, Zhongcheng H, Ying S,
Ru C, Rong X and Jiang L: Genetic variations associated with
telomere length affect the risk of gastric carcinoma. Medicine
(Baltimore). 99:e205512020. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Du J, Zhu X, Xie C, Dai N, Gu Y, Zhu M,
Wang C, Gao Y, Pan F, Ren C, et al: Telomere length, genetic
variants and gastric cancer risk in a Chinese population.
Carcinogenesis. 36:963–970. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Choi BJ, Yoon JH, Kim O, Choi WS, Nam SW,
Lee JY and Park WS: Influence of the hTERT rs2736100 polymorphism
on telomere length in gastric cancer. World J Gastroenterol.
21:9328–9336. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Campa D, Matarazzi M, Greenhalf W, Bijlsma
M, Saum KU, Pasquali C, van Laarhoven H, Szentesi A, Federici F,
Vodicka P, et al: Genetic determinants of telomere length and risk
of pancreatic cancer: A PANDoRA study. Int J Cancer. 144:1275–1283.
2019. View Article : Google Scholar
|
|
228
|
Duell EJ: Telomere length and pancreatic
cancer risk: Breaking down the evidence. Gut. 66:12017. View Article : Google Scholar
|
|
229
|
Luu HN, Huang JY, Wang R, Adams-Haduch J,
Jin A, Koh WP and Yuan JM: Association between leukocyte telomere
length and the risk of pancreatic cancer: Findings from a
prospective study. PLoS One. 14:e02216972019. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Campa D, Mergarten B, De Vivo I,
Boutron-Ruault MC, Racine A, Severi G, Nieters A, Katzke VA,
Trichopoulou A, Yiannakouris N, et al: Leukocyte telomere length in
relation to pancreatic cancer risk: A prospective study. Cancer
Epidemiol Biomarkers Prev. 23:2447–2454. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Mormile R: Telomere length and pancreatic
cancer risk-letter. Cancer Epidemiol Biomarkers Prev. 26:11572017.
View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Skinner HG, Gangnon RE, Litzelman K,
Johnson RA, Chari ST, Petersen GM and Boardman LA: Telomere length
and pancreatic cancer: A case-control study. Cancer Epidemiol
Biomarkers Prev. 21:2095–2100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Zhang R, Zhao J, Xu J and Liu F:
Association of peripheral leukocyte telomere length and its
variation with pancreatic cancer and colorectal cancer risk in
Chinese population. Oncotarget. 7:38579–38585. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Antwi SO, Bamlet WR, Broderick BT, Chaffee
KG, Oberg A, Jatoi A, Boardman LA and Petersen GM: Genetically
predicted telomere length is not associated with pancreatic cancer
risk. Cancer Epidemiol Biomarkers Prev. 26:971–974. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Antwi SO, Bamlet WR, Rabe KG, Cawthon RM,
Umudi I, Druliner BR, Sicotte H, Oberg AL, Jatoi A, Boardman LA and
Petersen GM: Leukocyte telomere length and its interaction with
germline variation in Telomere-Related genes in relation to
pancreatic adenocarcinoma risk. Cancer Epidemiol Biomarkers Prev.
29:1492–1500. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Hamada T, Yuan C, Bao Y, Zhang M, Khalaf
N, Babic A, Morales-Oyarvide V, Cochrane BB, Gaziano JM,
Giovannucci EL, et al: Prediagnostic leukocyte telomere length and
pancreatic cancer survival. Cancer Epidemiol Biomarkers Prev.
28:1868–1875. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Bao Y, Prescott J, Yuan C, Zhang M, Kraft
P, Babic A, Morales-Oyarvide V, Qian ZR, Buring JE, Cochrane BB, et
al: Leucocyte telomere length genetic variants at the TERT gene
region and risk of pancreatic cancer. Gut. 66:1116–1122. 2017.
View Article : Google Scholar
|
|
238
|
Posch A, Hofer-Zeni S, Klieser E,
Primavesi F, Naderlinger E, Brandstetter A, Filipits M, Urbas R,
Swiercynski S, Jäger T, et al: Hot Spot TERT promoter mutations are
rare in sporadic pancreatic neuroendocrine Neoplasms and associated
with telomere length and epigenetic expression patterns. Cancers
(Basel). 12:16252020. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Mormile R: Leukocyte telomere length and
pancreatic cancer survival: A consequence of activation of IL-6
signaling pathway in the carcinogenic process? J Gastrointest
Cancer. 51:720–721. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Kroupa M, Rachakonda SK, Liska V, Srinivas
N, Urbanova M, Jiraskova K, Schneiderova M, Vycital O, Vymetalkova
V, Vodickova L, et al: Relationship of telomere length in
colorectal cancer patients with cancer phenotype and patient
prognosis Relationship of telomere length in colorectal cancer
patients with cancer phenotype and patient prognosis. Br J Cance.
121:344–350. 2019. View Article : Google Scholar
|
|
241
|
Lopez-Doriga A, Valle L, Alonso MH, Aussó
S, Closa A, Sanjuan X, Barquero D, Rodríguez-Moranta F,
Sanz-Pamplona R and Moreno V: Telomere length alterations in
microsatellite stable colorectal cancer and association with the
immune response. Biochim Biophys Acta Mol Basis Dis.
1864:2992–3000. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Piñol-Felis C, Fernández-Marcelo T,
Viñas-Salas J and Valls-Bautista C: Telomeres and telomerase in the
clinical management of colorectal cancer. Clin Transl Oncol.
19:399–408. 2017. View Article : Google Scholar
|
|
243
|
Balc'h EL, Grandin N, Demattei MV,
Guyétant S, Tallet A, Pagès JC, Ouaissi M, Lecomte and Charbonneau
M: Measurement of telomere length in colorectal cancers for
improved molecular diagnosis. Int J Mol Sci. 18:18712017.
View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Luu HN, Qi M, Wang R, Adams-Haduch J,
Miljkovic I, Opresko PL, Jin A, Koh WP and Yuan JM: Association
between leukocyte telomere length and colorectal cancer risk in the
Singapore Chinese Health Study. Clin Transl Gastroenterol. 10:1–9.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Peacock SD, Massey TE, Vanner SJ and King
WD: Telomere length in the colon is related to colorectal adenoma
prevalence. PLoS One. 13:e02056972018. View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Naing C, Aung K, Lai PK and Mak JW:
Association between telomere length and the risk of colorectal
cancer: A meta-analysis of observational studies. BMC Cancer.
17:242017. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Aljarbou F, Almobarak A, Binrayes A and
Alamri HM: The expression of telomere-related proteins and DNA
damage response and their association with telomere length in
colorectal cancer in Saudi patients. PLoS One. 13:e01971542018.
View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Park WJ, Bae SU, Heo YR, Jung SJ and Lee
JH: Telomere shortening in non-tumorous and tumor mucosa is
independently related to colorectal carcinogenesis in precancerous
lesions. Int J Mol Epidemiol Genet. 8:53–58. 2017.PubMed/NCBI
|
|
249
|
Li J, Chang J, Tian J, Ke J, Zhu Y, Yang
Y, Gong Y, Zou D, Peng X, Yang N, et al: A Rare Variant P507L in
TPP1 interrupts TPP1-TIN2 interaction, influences telomere length,
and confers colorectal cancer risk in Chinese population. Cancer
Epidemiol Biomarkers Prev. 27:1029–1035. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Ridout KK, Ridout SJ, Price LH, Sen S and
Tyrka AR: Depression and telomere length: A meta-analysis. J Affect
Disord. 191:237–247. 2016. View Article : Google Scholar :
|
|
251
|
AlAhwal MS, Zaben FA, Sehlo MG, Khalifa
DA, Al-Aama JY, Edris S, Ashy JA and Koenig HG: Depression and
telomere length in colorectal cancer patients in Saudi Arabia.
Asian J Psychiatr. 40:130–131. 2019. View Article : Google Scholar
|
|
252
|
Ko E, Seo HW and Jung G: Telomere length
and reactive oxygen species levels are positively associated with a
high risk of mortality and recurrence in hepatocellular carcinoma.
Hepatology. 67:1378–1391. 2018. View Article : Google Scholar
|
|
253
|
Ma LJ, Wang XY, Duan M, Liu LZ, Shi JY,
Dong LQ, Yang LX, Wang ZC, Ding ZB and Ke AW: Telomere length
variation in tumor cells and cancer-associated fibroblasts:
Potential biomarker for hepatocellular carcinoma. J Pathol.
243:407–417. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
254
|
Lee HW, Park TI, Jang SY, Park SY, Park
WJ, Jung SJ and Lee JH: Clinicopathological characteristics of TERT
promoter mutation and telomere length in hepatocellular carcinoma.
Medicine (Baltimore). 96:e57662017. View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Ningarhari M, Caruso S, Hirsch TZ, Bayard
Q, Franconi A, Védie AL, Noblet B, Blanc JF, Amaddeo G, Ganne N, et
al: Telomere length is key to hepatocellular carcinoma diversity
and telomerase addiction is an actionable therapeutic target. J
Hepatol. 74:1155–1166. 2021. View Article : Google Scholar
|
|
256
|
Zeng H, Wu HC, Wang Q, Yang HI, Chen CJ,
Santella RM and Shen J: Telomere length and risk of hepatocellular
carcinoma: A nested Case-control study in Taiwan cancer screening
program cohort. Anticancer Res. 37:637–644. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Cheng Y, Yu C, Huang M, Du F, Song C, Ma
Z, Zhai X, Yang Y, Liu J, Bei JX, et al: Genetic association of
telomere length with hepatocellular carcinoma risk: A Mendelian
randomization analysis. Cancer Epidemiol. 50:39–45. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
258
|
Feng W, Yu D, Li B, Luo OY, Xu T, Cao Y
and Ding Y: Paired assessment of liver telomere lengths in
hepatocellular cancer is a reliable predictor of disease
persistence. Biosci Rep. 37:BSR201606212017. View Article : Google Scholar : PubMed/NCBI
|
|
259
|
Nikolouzakis TK, Stivaktakis PD, Apalaki
P, Kalliantasi K, Sapsakos TM, Spandidos DA, Tsatsakis A, Souglakos
J and Tsiaoussis J: Effect of systemic treatment on the micronuclei
frequency in the peripheral blood of patients with metastatic
colorectal cancer. Oncol Lett. 17:2703–2712. 2019.PubMed/NCBI
|
|
260
|
Nikolouzakis TK, Vakonaki E, Stivaktakis
PD, Alegakis A, Berdiaki A, Razos N, Souglakos J, Tsatsakis A and
Tsiaoussis J: Novel prognostic biomarkers in metastatic and locally
advanced colorectal cancer: Micronuclei frequency and telomerase
activity in peripheral blood lymphocytes. Front Oncol.
11:6836052021. View Article : Google Scholar : PubMed/NCBI
|
|
261
|
Guterres AN and Villanueva J: Targeting
telomerase for cancer therapy. Oncogene. 39:5811–5824. 2020.
View Article : Google Scholar : PubMed/NCBI
|
